M Isabel Casanova, Sangwan Park, Melaney A Mayes, Karolina Roszak, Michelle Ferneding, Nayeli Echeverria, Morgan A W Bowman, Sarah R Michalak, Monica Ardon, Sydni Wong, Sophie M Le, Nicole Daley, Brian C Leonard, Kathryn L Good, Jennifer Y Li, Sara M Thomasy
This study evaluated the tolerability and efficacy of the topical rho-kinase inhibitor netarsudil for canine primary corneal endothelial degeneration (PCED). Twenty-six eyes of 21 client-owned dogs with PCED were enrolled in a prospective, randomized, vehicle control clinical trial and received topical netarsudil 0.02% (Rhopressa®) or vehicle control twice daily (BID) for the first 4 months. Then, all patients received netarsudil for the next 4 or 8 months. Complete ophthalmic examination, ultrasonic pachymetry, Fourier-domain optical coherence tomography, and in vivo confocal microscopy were performed at baseline and 1, 2, 4, 6, 8 and 12 months...
March 14, 2024: Scientific Reports